Dogwood Therapeutics Files 8-K with Exhibits
Ticker: DWTX · Form: 8-K · Filed: Apr 3, 2025 · CIK: 1818844
| Field | Detail |
|---|---|
| Company | Dogwood Therapeutics, INC. (DWTX) |
| Form Type | 8-K |
| Filed Date | Apr 3, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, regulatory-filing, financial-statements
TL;DR
Dogwood Therapeutics (fka Virios) filed an 8-K, mostly exhibits. No major news.
AI Summary
On April 3, 2025, Dogwood Therapeutics, Inc. (formerly Virios Therapeutics, Inc.) filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material events or transactions detailed in the provided text.
Why It Matters
This filing indicates Dogwood Therapeutics, Inc. is meeting its regulatory reporting requirements, though it doesn't disclose new material business information.
Risk Assessment
Risk Level: low — The filing is a routine regulatory submission and does not contain information that suggests a change in the company's risk profile.
Key Players & Entities
- Dogwood Therapeutics, Inc. (company) — Registrant
- Virios Therapeutics, Inc. (company) — Former name of Registrant
- April 3, 2025 (date) — Date of Report
- 0001558370-25-004362 (filing_id) — Accession Number
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report financial statements and exhibits as of April 3, 2025.
What was Dogwood Therapeutics, Inc. formerly known as?
Dogwood Therapeutics, Inc. was formerly known as Virios Therapeutics, Inc.
On what date was this 8-K filed?
This 8-K was filed on April 3, 2025.
What is the state of incorporation for Dogwood Therapeutics, Inc.?
Dogwood Therapeutics, Inc. is incorporated in Delaware.
What is the principal executive office address for Dogwood Therapeutics, Inc.?
The principal executive office address is 44 Milton Avenue, Alpharetta, GA 30009.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 3, 2025 regarding Dogwood Therapeutics, Inc. (DWTX).